Broker recommendations for Novartis AG
The Novartis AG stock is rated at 1.522727 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Thursday 9 July, 2020 by a total of 22 brokers. This means that the consensus of the 22 different brokers is leaning toward to overweight (moderate buy).
2 (9.09%) Underweight
0 (0%) Hold
6 (27.27%) Overweight
3 (13.64%) Buy
Price target by analysts
The 18 latest analyst estimates, per Saturday 1 August, 2020, show the following high, low and average price targets.
Target Average: 102.64 USD
Target High: 115.8 USD
Target Low: 82.44 USD
Novartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma
Tuesday, 4 August 2020, 07:15:08
Global ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory follicular lymphoma as measured by complete response rate Kymriah previously…
SEC’s Pathetic Agreement With Bausch Health Companies
Monday, 3 August 2020, 23:10:23
Whitney Tilson’s email to investors discussing SEC’s pathetic agreement with Bausch Health Companies Inc (NYSE:BHC) (formerly Valeant); Insys documentary; Opioids, Bribery, and Wall Street; Novartis bribery settlement; Kodak. Q2 2020 hedge fund letters, conferences and more SEC’s Pathetic Agreement With Bausch Health Companies 1) On Friday, the U.S. Securities and Exchange Commission (“SEC”) announced a […] The post SEC’s Pathetic Agreement With Bausch Health Companies appeared first on ValueWalk .
Collaborating to explore new gene regulation therapies | Novartis
Thursday, 30 July 2020, 15:34:00
Novartis and Sangamo Therapeutics plan to pursue potential treatments for neurodevelopmental diseases.
Thursday, 30 July 2020, 04:00:00
Technavio has been monitoring the allergy rhinitis drugs market and it is poised to grow by USD 2.4 bn during 2020-2024, progressing at a CAGR of almost 4% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200729005699/en/ Technavio has announced its latest market research report titled Global Allergy Rhinitis Drugs Market 2020-2024 (Graphic: Business Wire). Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Latest Free Sample Report on COVID-19 Impact The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Alcon Inc., ALK-Abello AS, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, and Stallergenes Greer Ltd. are some of the major market participants.
The Big Interview: Novartis CTO Elizabeth Theophille
Wednesday, 29 July 2020, 15:10:18
“One of our big focuses for the next four-six years will be to refresh our SAP landscape which will require a complete overhaul…” The post The Big Interview: Novartis CTO Elizabeth Theophille appeared first on Computer Business Review .
— Computer Business Review Online